S5446
Anti-SUMO-1 (C-terminal) antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-GMP1, Anti-PIC1, Anti-SMT3C, Anti-SMT3H3, Anti-Sentrin-1, Anti-Small Ubiquitin-related modifier-1, Anti-UBL1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 14 kDa
species reactivity
human
technique(s)
microarray: suitable
western blot: 1-2 μg/mL using nuclear extract of the human epitheloid carcinoma HeLa cell line
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
cow ... SUMO1(614967)
human ... SUMO1(7341)
mouse ... Sumo1(22218)
rat ... Sumo1(301442)
General description
Small ubiquitin-related modifier 1 (SUMO-1) is a highly conserved small ubiquitin-related modifier, also known as sentrin. SUMO-1 gene is mapped to human chromosome 2q33.1.
Specificity
Anti-SUMO-1 (C-terminal) recognizes unconjugated SUMO-1 (14 kDa), SUMO-1-fusion protein, as well as proteins covalently conjugated to SUMO-1, eg. RanGAP1, 90kDa
Immunogen
synthetic peptide corresponding to amino acids 86-97 located at the C-terminus of human SUMO-1, conjugated to KLH. This sequence is identical in many species including rat, mouse, bovine, chicken, and Xenopus, and highly conserved (single amino acid substitution) in C. elegans SMT3. The sequence has only 66% homology to human SUMO-2 and SUMO-3.
Application
Anti-SUMO-1 (C-terminal) antibody produced in rabbit has been used in immunoblotting.
Biochem/physiol Actions
Small ubiquitin-related modifier 1 (SUMO-1) is covalently conjugated to the lysine side in proteins through its C-terminal glycine residue by an isopeptide bond. Their conjugation with cellular proteins has been correlated wide variety of biological processes including inflammation, oncogenesis nuclear transport, cell cycle control and viral infection response. SUMO-1 serves as a substrate for Ran GTPase-activating protein (RanGAP1). Unmodified RanGAP1 is present in the cytoplasm, suggesting that modification by SUMO-1 may target RanGAP1 to the nuclear pore complex (NPC). Haploinsufficiency in the SUMO-1 gene is implicated in the Cleft Lip and Palate.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin and 15 mM sodium azide.
Storage and Stability
For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Soraya Beiraghi et al.
American journal of human genetics, 81(1), 180-188 (2007-06-15)
Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is one of the most common congenital facial defects, with an incidence of 1 in 700-1,000 live births among individuals of European descent. Several linkage and association studies of NSCL/P have
Aleksandra Fergin et al.
PLoS genetics, 18(6), e1009978-e1009978 (2022-06-07)
The sumoylation (SUMO) pathway is involved in a variety of processes during C. elegans development, such as gonadal and vulval fate specification, cell cycle progression and maintenance of chromosome structure. The ubiquitous expression and pleiotropic effects have made it difficult
Fowzan S Alkuraya et al.
Science (New York, N.Y.), 313(5794), 1751-1751 (2006-09-23)
The posttranslational modification sumoylation can have multiple effects on its substrate proteins. We studied a patient with isolated cleft lip and palate and a balanced chromosomal translocation that disrupts the SUMO1 (small ubiquitin-related modifier) gene, resulting in haploinsufficiency. In mouse
H Saitoh et al.
The Journal of biological chemistry, 275(9), 6252-6258 (2000-02-29)
Post-translational modification marked by the covalent attachment of the ubiquitin-like protein SUMO-1/SMT3C has been implicated in a wide variety of cellular processes. Recently, two cDNAs encoding proteins related to SUMO-1 have been identified in human and mouse. The functions and
Xiuling Li et al.
Development (Cambridge, England), 139(23), 4321-4329 (2012-11-08)
In vertebrates, establishment of the hematopoietic stem/progenitor cell (HSPC) pool involves mobilization of these cells in successive developmental hematopoietic niches. In zebrafish, HSPCs originate from the ventral wall of the dorsal aorta (VDA), the equivalent of the mammalian aorta-gonad-mesonephros (AGM).
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service